现代肿瘤医学
現代腫瘤醫學
현대종류의학
JOURNAL OF MODERN ONCOLOGY
2014年
10期
2315-2318
,共4页
王浩%郭俊俊%王锋刚%张永彤%白艳霞%郭亚焕
王浩%郭俊俊%王鋒剛%張永彤%白豔霞%郭亞煥
왕호%곽준준%왕봉강%장영동%백염하%곽아환
小细胞肺癌%放疗%化疗%预后
小細胞肺癌%放療%化療%預後
소세포폐암%방료%화료%예후
small cell lung cancer%radiotherapy%chemotherapy%prognesis
目的:回顾性分析我院93例广泛期SCLC放化综合治疗的疗效,对影响小细胞肺癌预后的多个因素进行分析。方法:选取2008年10月-2010年10月,陕西省肿瘤医院放疗科收治的经病理学或细胞学证实的93例广泛期SCLC患者,患者均采用放化综合治疗。对比风险模型进行多因素分析。主要收集患者的年龄、性别、分期、PS评分、转移部位、胸部放疗情况、化疗周期、预防性脑放疗情况,观察中位生存时间、总生存时间。结果:93例患者的1年生存率39.8%,2年生存率11.8%,3年生存率2.18%,中位生存期11.56个月。单因素分析显示PS评分、胸部放疗、预防性脑放疗、化疗周期数、脑转移对患者的生存期有影响。多因素分析显示PS评分、预防性脑放疗、化疗周期数是预测广泛期小细胞肺癌预后的因素。结论:对于广泛期小细胞肺癌患者PS评分<2、化疗周期数≥4、预防性脑放疗均提示其预后较好。
目的:迴顧性分析我院93例廣汎期SCLC放化綜閤治療的療效,對影響小細胞肺癌預後的多箇因素進行分析。方法:選取2008年10月-2010年10月,陝西省腫瘤醫院放療科收治的經病理學或細胞學證實的93例廣汎期SCLC患者,患者均採用放化綜閤治療。對比風險模型進行多因素分析。主要收集患者的年齡、性彆、分期、PS評分、轉移部位、胸部放療情況、化療週期、預防性腦放療情況,觀察中位生存時間、總生存時間。結果:93例患者的1年生存率39.8%,2年生存率11.8%,3年生存率2.18%,中位生存期11.56箇月。單因素分析顯示PS評分、胸部放療、預防性腦放療、化療週期數、腦轉移對患者的生存期有影響。多因素分析顯示PS評分、預防性腦放療、化療週期數是預測廣汎期小細胞肺癌預後的因素。結論:對于廣汎期小細胞肺癌患者PS評分<2、化療週期數≥4、預防性腦放療均提示其預後較好。
목적:회고성분석아원93례엄범기SCLC방화종합치료적료효,대영향소세포폐암예후적다개인소진행분석。방법:선취2008년10월-2010년10월,합서성종류의원방료과수치적경병이학혹세포학증실적93례엄범기SCLC환자,환자균채용방화종합치료。대비풍험모형진행다인소분석。주요수집환자적년령、성별、분기、PS평분、전이부위、흉부방료정황、화료주기、예방성뇌방료정황,관찰중위생존시간、총생존시간。결과:93례환자적1년생존솔39.8%,2년생존솔11.8%,3년생존솔2.18%,중위생존기11.56개월。단인소분석현시PS평분、흉부방료、예방성뇌방료、화료주기수、뇌전이대환자적생존기유영향。다인소분석현시PS평분、예방성뇌방료、화료주기수시예측엄범기소세포폐암예후적인소。결론:대우엄범기소세포폐암환자PS평분<2、화료주기수≥4、예방성뇌방료균제시기예후교호。
Objective:To retrospectively review the prognostic factors for 93 patients who underwent the multimo-dality treatment of radiothrapy combined with chemotherapy. All the factors were analyzed by Kaplan-Meier and COX multivariate propotional hazards model. Methods:Retrospective study was carried on 93 patients with small cell lung cancer in extensive-stage from October of 2008 to October of 2010 in Shaanxi Province Tumor Hospital. The multiva-riate analysis was performed with Coxˊs proportion risk model. To analyze the general status,stages,PS score,metastat-ic sites,chemotherapy cycles,prophylactic cranial irradiation,median survival time and overall survival. Results:The overall 1-year survival rate was 39. 8%,2-year survival rate was 11. 8% and 3-year survival rate was 2. 18%. The median survival time was 11. 56 months. The univariate analysis showed that PS score,the absence or presence of brain metastasis,chemotherapy times,thoracic radiotherapy,prophylactic cranial irradiation were related to survival period. The multivariate analysis indicated that the number of chemotherapy,prophylactic cranial irradiation,and PS score were related to the prognosis of patients. Conclusion:The patients who can accept more than four cycles chemo-therapy or accept prophylactic cranial irradiation or PS score 0 -1 have longer survival time and they would benet from multi-treatment modalities.